Norway’s NBIM, the world’s largest sovereign wealth fund and a key Tesla shareholder, has rejected Elon Musk’s $1 trillion compensation plan, citing concerns over its scale and risk, sending Tesla shares lower in pre-market trading.
#YonhapInfomax #Tesla #ElonMusk #NBIM #CompensationPlan #ShareholderOpposition #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=89197
Norway Sovereign Wealth Fund, Major Tesla Shareholder, Rejects $1 Trillion Musk Compensation Plan
Norway’s NBIM, the world’s largest sovereign wealth fund and a key Tesla shareholder, has rejected Elon Musk’s $1 trillion compensation plan, citing concerns over its scale and risk, sending Tesla shares lower in pre-market trading.
ISC Co., a subsidiary of SKC, will absorb its wholly owned unit iSemi to streamline operations, with the board closely monitoring shareholder opposition and approving the merger amid positive investor sentiment.
#YonhapInfomax #ISC #SKC #SubsidiaryMerger #ShareholderOpposition #SemiconductorTestSolutions #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=78136
ISC Absorbs Subsidiary, Independent Directors Weigh Shareholder Opposition
ISC Co., a subsidiary of SKC, will absorb its wholly owned unit iSemi to streamline operations, with the board closely monitoring shareholder opposition and approving the merger amid positive investor sentiment.
Two Seas Capital, Core Scientific’s third-largest shareholder, has publicly opposed CoreWeave’s all-stock acquisition offer, citing structural flaws and undervaluation, as both companies’ shares decline following the proposal.
#YonhapInfomax #CoreScientific #CoreWeave #AcquisitionProposal #ShareholderOpposition #SharePriceTrend #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=76270PharmaResearch Co. has denied tunneling allegations in its dealings with Pixelity, asserting that all transactions were fair and market-based, but investor skepticism persists amid ongoing governance concerns.
#YonhapInfomax #PharmaResearch #Pixelity #TunnelingAllegations #ShareholderOpposition #RevenueDependence #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=70849
PharmaResearch Addresses Tunneling Allegations—'Transactions with Pixelity Were Fair'
PharmaResearch Co. has denied tunneling allegations in its dealings with Pixelity, asserting that all transactions were fair and market-based, but investor skepticism persists amid ongoing governance concerns.
Yonhap Infomax News